Proteomics Market

Executive Summary

Proteomics Market was valued at US $25.31 billion in 2021 and is projected to grow at 13.51% CAGR over the forecast period to reach US $54.14 billion by 2027. Proteomics Market represented US $5.67 billion opportunity over 2019-2021 and estimated to create US $28.83 billion opportunity in 2027 over 2021.

Proteomics from Consainsights analyses the Proteomics Market in the Life Sciences industry over the forecast period to 2027.

Proteomics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Proteomics segmentation includes Instrumentation Technology, Reagent, Service & Software, Application, End-user, Region and Geography.

Based on the Instrumentation Technology, the Proteomics analysis covers Pricing Analysis, Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, Surface Plasmon Resonance, Protein Fractionation.

In Instrumentation Technology segment, Pricing Analysis segment has highest cagr growth of 11.92%.

Based on the Reagent, the Proteomics analysis covers Immunoassay Reagents, Spectroscopy Reagents, Chromatography Reagents, Protein Microarray Reagents, X-Ray Crystallography Reagents, Electrophoresis Reagents, Protein Fractionation Reagents.

In Reagent segment, Immunoassay Reagents segment has highest cagr growth of 11.92%.

Based on the Service & Software, the Proteomics analysis covers Core Proteomics Services, Bioinformatics Software & Services.

In Service & Software segment, Core Proteomics Services segment has highest cagr growth of 11.92%.

Based on the Application, the Proteomics analysis covers Clinical Diagnostics, Drug Discovery, Other Applications.

In Application segment, Clinical Diagnostics segment has highest cagr growth of 11.92%.

Based on the End-user, the Proteomics analysis covers Pharmaceutical Companies, Academic Research Laboratories, Hospitals, Clinical Laboratories, Other End-users.

In End-user segment, Pharmaceutical Companies segment has highest cagr growth of 11.92%.

Based on the Region, the Proteomics analysis covers North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.

In Region segment, North America segment has highest cagr growth of 11.92%.

Based on the region, the Proteomics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Key Players, Other Players and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Instrumentation Technology

Introduction

In 2021, Pricing Analysis segment has the highest revenue of US $9.96 billion and is expected to grow at CAGR of 11.92% by 2027 Pricing Analysis segment has highest cagr growth of 11.92%.

Pricing Analysis

Pricing Analysis segment was valued at US $7.73 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $21.30 billion by 2027. Pricing Analysis segment represented US $2.23 billion opportunity over 2019-2021 and estimated to create US $11.34 billion opportunity in 2027 over 2021.

Spectroscopy

Spectroscopy segment was valued at US $4.62 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $12.73 billion by 2027. Spectroscopy segment represented US $1.33 billion opportunity over 2019-2021 and estimated to create US $6.78 billion opportunity in 2027 over 2021.

Chromatography

Chromatography segment was valued at US $3.12 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $8.59 billion by 2027. Chromatography segment represented US $0.90 billion opportunity over 2019-2021 and estimated to create US $4.57 billion opportunity in 2027 over 2021.

Electrophoresis

Electrophoresis segment was valued at US $1.74 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $4.79 billion by 2027. Electrophoresis segment represented US $0.50 billion opportunity over 2019-2021 and estimated to create US $2.55 billion opportunity in 2027 over 2021.

Protein Microarrays

Protein Microarrays segment was valued at US $0.99 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $2.73 billion by 2027. Protein Microarrays segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.45 billion opportunity in 2027 over 2021.

X-Ray Crystallography

X-Ray Crystallography segment was valued at US $0.58 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $1.60 billion by 2027. X-Ray Crystallography segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.85 billion opportunity in 2027 over 2021.

Surface Plasmon Resonance

Surface Plasmon Resonance segment was valued at US $0.61 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $1.67 billion by 2027. Surface Plasmon Resonance segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.89 billion opportunity in 2027 over 2021.

Protein Fractionation

Protein Fractionation segment was valued at US $0.26 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $0.73 billion by 2027. Protein Fractionation segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.39 billion opportunity in 2027 over 2021.

Reagent

Introduction

In 2021, Immunoassay Reagents segment has the highest revenue of US $9.62 billion and is expected to grow at CAGR of 11.92% by 2027 Immunoassay Reagents segment has highest cagr growth of 11.92%.

Immunoassay Reagents

Immunoassay Reagents segment was valued at US $7.47 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $20.58 billion by 2027. Immunoassay Reagents segment represented US $2.15 billion opportunity over 2019-2021 and estimated to create US $10.96 billion opportunity in 2027 over 2021.

Spectroscopy Reagents

Spectroscopy Reagents segment was valued at US $4.65 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $12.82 billion by 2027. Spectroscopy Reagents segment represented US $1.34 billion opportunity over 2019-2021 and estimated to create US $6.83 billion opportunity in 2027 over 2021.

Chromatography Reagents

Chromatography Reagents segment was valued at US $3.17 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $8.73 billion by 2027. Chromatography Reagents segment represented US $0.91 billion opportunity over 2019-2021 and estimated to create US $4.65 billion opportunity in 2027 over 2021.

Protein Microarray Reagents

Protein Microarray Reagents segment was valued at US $1.87 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $5.16 billion by 2027. Protein Microarray Reagents segment represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $2.75 billion opportunity in 2027 over 2021.

X-Ray Crystallography Reagents

X-Ray Crystallography Reagents segment was valued at US $1.43 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $3.93 billion by 2027. X-Ray Crystallography Reagents segment represented US $0.41 billion opportunity over 2019-2021 and estimated to create US $2.09 billion opportunity in 2027 over 2021.

Electrophoresis Reagents

Electrophoresis Reagents segment was valued at US $0.95 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $2.62 billion by 2027. Electrophoresis Reagents segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $1.39 billion opportunity in 2027 over 2021.

Protein Fractionation Reagents

Protein Fractionation Reagents segment was valued at US $0.11 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $0.30 billion by 2027. Protein Fractionation Reagents segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.16 billion opportunity in 2027 over 2021.

Service & Software

Introduction

In 2021, Core Proteomics Services segment has the highest revenue of US $13.71 billion and is expected to grow at CAGR of 11.92% by 2027 Core Proteomics Services segment has highest cagr growth of 11.92%.

Core Proteomics Services

Core Proteomics Services segment was valued at US $10.64 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $29.32 billion by 2027. Core Proteomics Services segment represented US $3.07 billion opportunity over 2019-2021 and estimated to create US $15.61 billion opportunity in 2027 over 2021.

Bioinformatics Software & Services

Bioinformatics Software & Services segment was valued at US $9.01 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $24.82 billion by 2027. Bioinformatics Software & Services segment represented US $2.60 billion opportunity over 2019-2021 and estimated to create US $13.22 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Clinical Diagnostics segment has the highest revenue of US $11.73 billion and is expected to grow at CAGR of 11.92% by 2027 Clinical Diagnostics segment has highest cagr growth of 11.92%.

Clinical Diagnostics

Clinical Diagnostics segment was valued at US $9.11 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $25.10 billion by 2027. Clinical Diagnostics segment represented US $2.63 billion opportunity over 2019-2021 and estimated to create US $13.36 billion opportunity in 2027 over 2021.

Drug Discovery

Drug Discovery segment was valued at US $8.39 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $23.13 billion by 2027. Drug Discovery segment represented US $2.42 billion opportunity over 2019-2021 and estimated to create US $12.31 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $2.15 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $5.92 billion by 2027. Other Applications segment represented US $0.62 billion opportunity over 2019-2021 and estimated to create US $3.15 billion opportunity in 2027 over 2021.

End-user

Introduction

In 2021, Pharmaceutical Companies segment has the highest revenue of US $10.76 billion and is expected to grow at CAGR of 11.92% by 2027 Pharmaceutical Companies segment has highest cagr growth of 11.92%.

Pharmaceutical Companies

Pharmaceutical Companies segment was valued at US $8.35 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $23.02 billion by 2027. Pharmaceutical Companies segment represented US $2.41 billion opportunity over 2019-2021 and estimated to create US $12.26 billion opportunity in 2027 over 2021.

Academic Research Laboratories

Academic Research Laboratories segment was valued at US $5.75 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $15.85 billion by 2027. Academic Research Laboratories segment represented US $1.66 billion opportunity over 2019-2021 and estimated to create US $8.44 billion opportunity in 2027 over 2021.

Hospitals

Hospitals segment was valued at US $2.02 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $5.57 billion by 2027. Hospitals segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.97 billion opportunity in 2027 over 2021.

Clinical Laboratories

Clinical Laboratories segment was valued at US $1.88 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $5.18 billion by 2027. Clinical Laboratories segment represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $2.76 billion opportunity in 2027 over 2021.

Other End-users

Other End-users segment was valued at US $1.64 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $4.52 billion by 2027. Other End-users segment represented US $0.47 billion opportunity over 2019-2021 and estimated to create US $2.41 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $10.98 billion and is expected to grow at CAGR of 11.92% by 2027 North America segment has highest cagr growth of 11.92%.

North America

North America segment was valued at US $8.53 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $23.49 billion by 2027. North America segment represented US $2.46 billion opportunity over 2019-2021 and estimated to create US $12.51 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $5.02 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $13.83 billion by 2027. Europe segment represented US $1.45 billion opportunity over 2019-2021 and estimated to create US $7.37 billion opportunity in 2027 over 2021.

Asia-Pacific

Asia-Pacific segment was valued at US $3.46 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $9.52 billion by 2027. Asia-Pacific segment represented US $1.00 billion opportunity over 2019-2021 and estimated to create US $5.07 billion opportunity in 2027 over 2021.

Latin America

Latin America segment was valued at US $1.81 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $4.98 billion by 2027. Latin America segment represented US $0.52 billion opportunity over 2019-2021 and estimated to create US $2.65 billion opportunity in 2027 over 2021.

Middle East & Africa

Middle East & Africa segment was valued at US $0.84 billion in 2019 and is projected to grow at 11.92% CAGR over the forecast period to reach US $2.31 billion by 2027. Middle East & Africa segment represented US $0.24 billion opportunity over 2019-2021 and estimated to create US $1.23 billion opportunity in 2027 over 2021.